References

Halki Diabetes Remedy

Diabetes Free Forever

Get Instant Access

[1] Herlitz J. How to improve the cardiac prognosis for diabetes. Diabetes Care 1999;22(Suppl 2):B89-96.

[2] Fagan TC, Deedwania PC. The cardiovascular dys-metabolic syndrome. Am J Med 1998;105(1A): 77S-82S.

[3] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

[4] UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

[5] UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of both mac-rovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713-20.

[6] Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care 1998;21(Suppl 3):C3-6.

[7] Tarnow L, Rossing P, Gall M-A, et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-51.

[8] Hypertension in diabetes study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertension 1993;11:309-17.

[9] Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995; 25:305-13.

[10] DeStafano F, Ford ES, Newman J, Stevenson JM, Wetterhall SF, Anda RF, et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993;3:27-34.

[11] Criqui MH. Epidemiology of atherosclerosis: an updated overview. Am J Cardiol 1986;57:18C-23C.

[12] Wilson PW. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Framingham Heart Study. Am J Car-diol 1997;80(9B):3J-8J.

[13] The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994;23: 145-58.

[14] Systolic hypertension in Europe trial investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.

[15] Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34:795-808.

[16] Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD and Dominic Hodgkin, PhD. Am J Manag Care 1998;4(12 Suppl):S765-9 [discussion S770].

[17] UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;12;317(7160):720-6.

[18] Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 2000;8; 160(9):1277-83.

[19] The Sixth Report of The Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.

[20] Prencipe M, Casini AR, Santini M, Ferretti C, Scaldaferri N, Culasso F. Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey. J Hum Hypertens 2000;14:825-30.

[21] Kjeldsen SE, Dahlof B, Devereux RB, Julius S, de Faire U, Fyhrquist F, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losar-tan Intervention For Endpoint. Am J Hypertens 2000;13:899-906.

[22] American Diabetes Association. Position statement: treatment of hypertension in adults with diabetes. 2002;25:571-3.

[23] 1999 Canadian recommendations for the management of hypertension. CMAJ 1999;161(12 Suppl): S1-17.

[24] Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.

[25] Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. CMAJ 2000;163(2):188-92.

[26] Hansson L, Lindholm LH, Niskanen L, Lanke J, Hendner T, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-6.

[27] The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-53.

[28] Galletti F, Strazzullo P, Capaldo B, Carretta R, Fabris F, Ferrara LA, et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 1999;17:439-45.

[29] Buller GK, Perazella M. ACE inhibitor-induced hypoglycaemia. Am J Med 1991;91:104-5.

[30] Heart Outcomes Prevention Evaluation (HOPE) study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.

[31] Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998;12;158(1):26-32.

[32] Goodfriend TL, Elliott ME, Catt KJ. Drug therapy: angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.

[33] Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme, ACE inhibitors. CMAJ 2000;163:293-6.

[34] Piepho RW. Overview of the angiotensin-convert-ing-enzyme inhibitors. Am J Health Syst Pharm 2001;57(Suppl 1):S3-7.

[35] Warner KK, Visconti JA, Tschampel MM. Angio-tensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000;34:526-8.

[36] Grossman E. Angiotensin II receptor blockers. Arch Intern Med 2000;160:1905-11.

[37] Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, et al. ACE inhibition or an-giotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000;58:2084-92.

[38] Shah S, Khatri I, Freis ED. Mechanism of antihy-pertensive effect of thiazide diuretics. Am Heart J 1978;95(5):611-8.

[39] Weidmann PO, BoehlenL, deCourtenM. Pathogen-esis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993;125:1498-513.

[40] Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based an-tihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.

[41] Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens 1995; 8(12 Pt 1):1147-53.

[42] Warram J, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991;151:1350-6.

[43] David S, Siscovick TE, Raghunathan BM, Psaty TD, Koepsell KG, Wicklund XL, et al. Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest. N Engl J Med 1994; 330:1852-7.

[44] Zuanetti G, Latini R. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. J Diabet Complications 1997; 11:131-6.

[45] Gress TW, Nieto J, Shahar I, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. For the atherosclerosis risk in communities study. N Engl J Med 2000;342: 905-12.

[46] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydro-chlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension 1985;7:1008-16.

[47] Ravid M, Brosh D, Levi Z, Bar-Dayan Y, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8.

[48] Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. BMJ 1976;2:272-3.

[49] Kerr D, Macdonald IA, Heller SR, et al. Beta-adrenoceptor blockade and hypoglycaema. Br J Clin Pharmacol 1990;29:685-93.

[50] Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes 1991; 40(9):1177-86.

[51] Lyngsoe J, Sorensen M, Sjostrand H, et al. The effect of sustained release verapamil on glucose metabolism in patients with NIDDM. Drugs 1992;1: 85-7.

[52] HanssonL,ZanchettiA,CarruthersSG,etal. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.

[53] Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.

[54] Tatti P, Pahor M, Byington R. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21: 597-603.

[55] Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (bena-zepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7.

[56] Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996;9:150S-4S.

[57] Andersen P, Seljeflot I, Herzog A. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-age men. J Cardiovasc Pharmacol 1998;31:677-83.

[58] The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. JAMA 2000;283:1967-75.

[59] Bauer JH, Jones LB, Gaddy P. Effects of prazosin therapy on blood pressure, renal function, and body fluid composition. Arch Intern Med 1984;114: 1196-200.

[60] Leenen FHH, Smith DL, Faraks RM, Reeves RA, Marquez-Julio A. Vasodilators and regression ofleft ventricular hypertrophy: hydralazine versus prazo-sin in hypertensive patients. Am J Med 1987;82: 969-78.

[61] Liebson PR, Grandits GA, Dianzumba S. Comparison of 5 antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study. Circulation 1995; 91:698-706.

[62] Gottdiener JS, Reda DJ, Massie BM. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997;95: 2007-14.

[63] Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11(Suppl F):13F-9F.

[64] Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbu-minuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-4.

[65] Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58(2):762-9.

[66] Pohl M, Cooper M, Ulrey J, Pauls J, Rohse R. Safety and efficacy of irbesartan in hypertensive patients with type 2 diabetes and proteinuria [abstract]. Am J Hypertens 1997;10:105A.

[67] Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al. Comparison of antihyper-tensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18(11):1671-5.

[68] Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al, for the STOP-Hyperten-sion-2 study group. Randomised trial ofold and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.

[69] Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al, for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.

[70] Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.

[71] Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-62.

[72] Ravid M, Broth D, Levi Z, Bar-Dayan Y, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8.

[73] Mogensen CE. Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 1994;72(3 Suppl):S38-45.

[74] Ruddy M. Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens 2002;15:466.

[75] Estacio RO, Jeffers BW, Gifford N, Dchrier RW. Effect of blood pressure control on diabetic micro-vascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2): B54-64.

[76] Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.

[77] Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997;29:641-50.

[78] Luscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993;21(2):305-9.

[79] Pittrow DB, Antlsperger A, Welzel D, Wambach G, Schardt W, Weidinger G. Evaluation of the efficacy and tolerability of a low-dose combination of isradi-pine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc Drugs Ther 1997;11(5):619-27.

[80] Plat F, Saini R. Management of hypertension: the role of combination therapy. Am J Hypertens 1997;10(10 Pt 2):262S-71S.

[81] Corcoran JS, Perkins JE, Hoffbrand BI, Yudkin JS. Treating hypertension in non-insulin-dependent diabetes: a comparison of atenolol, nifedipine, and cap-topril combined with bendrofluazide. Diabet Med 1987;4(2):164-8.

[82] Shigihara T, Sato A, Hayashi K, Saruta T. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive micro-albuminuric patients with type II diabetes. Hyper-tens Res 2000;23(3):219-26.

[83] Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropa-thy. Kidney Int 1998;54(4):1283-9.

[84] Souviron Rodriguez A, Martinez Morillo M. Captopril + hydrochlorothiazide versus capto-pril + nifedipine in the treatment of arterial hypertension in diabetes mellitus type II [abstract]. Rev Esp Cardiol 1992;45(7):432-7 [in Spanish].

[85] Schneider M, Lerch M, Papiri M, Buechel P, Boehlen L, Shaw S, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortali done treatment in hypertensive type 2 diabetes. J Hypertens 1993;14(5):669-77.

[86] Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999;12(8)(Pt 2):80S-5S.

[87] Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16:434-44.

[88] Sniderman A, Michel C, Racine N. Heart disease in patients with diabetes mellitus. J Clin Epidemiol 1992;45:1357-70.

ELSEVIER SAUNDERS

Cardiol Clin 23 (2005) 153-164

CARDIOLOGY CLINICS

Was this article helpful?

0 0
Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment